302P Clinicopathological features as a surrogate for the 21-gene recurrence score in early breast cancer adjuvant decision-making

May 1, 2026ESMO OpenOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to determine if clinicopathological features can serve as a surrogate for the 21-gene recurrence score in early breast cancer decision-making.
Case-control study with HR+ GBC cases and NPBC controls randomly assigned with a 1:2 ratio.
Clinical, pathology, and obstetric data were collected; primary tumors analyzed by RNA-seq and GeoMX digital spatial proteome profiling.
57 GBC cases and 114 NPBC controls were included in analysis.
3rd trimester GBC cases exhibited worse overall survival (OS) compared to NPBC controls.
GBC-PP showed significantly worse disease-free survival (DFS) and OS compared to 1GBC, with trends indicating worse OS compared to NPBC.
1GBC had better treatment response (RCB 0-I) to neoadjuvant chemotherapy than GBC-PP and NPBC.

Case-control study compares clinicopathological features to 21-gene score for adjuvant decisions in early breast cancer.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Sarmento et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share